About Us - Juniper Biosciences

Alex Agnoletto

CEO, Co-Founder & Board Member

Alex served previously as Evergreen Theragnostics' CFO, overseeing the finance function and CDMO business operations, and aided the $1B+ sale to Lantheus Holdings in 2025 (NASDAQ: LNTH). Previously he was the VP, Controller, and Interim-CFO at Blue Foundry Bancorp, a $2B bank, leading the accounting function in their 2021 IPO raising $277MM (NASDAQ: BLFY). He began his career in the audit practice at KPMG.

Dr. Indranil Nandi, PhD

COO & Co-Founder

Dr. Nandi is a seasoned pharmaceutical professional with nearly 25 years of experience, supporting and executing strategic operational initiatives to drive business growth. He possesses expertise in CMC, IP, portfolio and program management, specializing in regulatory filing, manufacturing, and product launches. Previously, he served as Chief Scientific Officer at Jubilant Radiopharma, VP of R&D at Impax Laboratories, and spent over a decade at Sandoz/Novartis. He holds a PhD from St. John's University and an MBA from Rutgers.

Dr. Kyle Hoffmann, PharmD

Director of Manufacturing, Co-Founder

Kyle has extensive experience in radiopharmaceutical manufacturing, nuclear pharmacy operations, and clinical pharmacy. Prior positions included VP of Manufacturing and Site Head at Evergreen Theragnostics, Facility Manager at SOFIE, and Pharmacy Manager at CVS Health. He earned a Doctor of Pharmacy degree from MCPHS University and a Masters in Radiation Health Physics from Oregon State University.

Dr. Serge Lyashchenko, PharmD

Advisor, Co-Founder & Board Member

Dr. Lyashchenko is a faculty member of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. He oversees the Radiochemistry and Molecular Imaging Probe Core at MSKCC and has translated 50+ agents into radiopharmaceutical development. He co-founded Evergreen Theragnostics and serves as an advisor to the IAEA and WHO regarding global radiopharmaceutical access.

Sharon Roded

Advisor, Co-Founder, Board Member

Sharon is a seasoned serial entrepreneur with over 25 years in the nuclear medicine industry. He currently serves as CEO of Marshall Isotopes and was a board member of Evergreen Theragnostics. He has founded and led companies across diverse industries while investing in innovative startup ventures.

Pietro Bubba Bello

Advisor, Board Member

Pietro graduated in Pharmacy from the University of Perugia and the School of Pharmacy in London. He began his career at Advanced Accelerator Applications, a radiopharmaceutical leader acquired by Novartis in 2018, managing various production sites in Italy and America. He currently serves as VP Manufacturing & Operations at BetaGlue Therapeutics.

Yehudah Livneh

Senior Advisor, Intellectual Property

Dr. Yehudah Livneh has more than 40 years of experience in intellectual property in the pharmaceutical and biotechnology industries, spanning innovative and generic pharmaceuticals, biosimilars, radiotheragnostics and biologics.

He spent more than 25 years at Teva Pharmaceutical Industries, where he held senior positions including General Patent Counsel and Vice President of Corporate Intellectual Property & Legislative Affairs, with responsibility for the company’s worldwide patent strategy. Since 2016, he has advised pharmaceutical and biotechnology companies on intellectual property strategy and policy.

Dr. Livneh is a registered Patent Attorney in Israel and Patent Agent in the United States and holds a Ph.D. in Molecular Biology–Biochemistry from Brandeis University.

Sean Campbell

General Counsel

Sean Campbell is General Counsel to Juniper Biosciences. Previously, Sean was an attorney in Lowenstein Sandler's Emerging Companies and Venture Capital practice group, where he worked closely with companies in radiopharmaceutical development, healthcare, and technology. Sean has guided companies in their growth from formation to exit, while solving for the wide-ranging legal, governance and financing matters which arise in between. Sean graduated magna cum laude from Rutgers Law School and is a member of the Order of the Coif. He is a dad of three young daughters and a Navy husband to his wife, who serves active duty.

Huw Jones

Senior Advisor, Commercial Strategy

Huw Jones is a 35-year veteran of the US and European pharmaceutical industries. Most recently he served as the Head of Sales and Marketing for Lantheus, successfully launching the first PET diagnostic blockbuster agent, Pylarify, an F-18 agent for men with prostate cancer. Prior to Lantheus Huw led the sales and marketing function for nuclear medicine's industry pioneer Advanced Accelerator Applications (AAA) following their successful IPO, and launched the first theranostic pair, Lutathera and Netspot, for the diagnosis and treatment of neuroendocrine tumors. Huw began his career at Novartis in the UK, and served in a Global Commercial role in Switzerland, covering immunosuppressants and oncology areas.

Richard Brodsky

Advisor, Commercial Lead

Rich Brodsky is a biopharma commercial strategy leader with over 25 years of industry experience at Pfizer and Alexion. Most recently, he led Global Marketing for the launch of Soliris in Myasthenia Gravis—the first MG therapy approved in 60 years and Alexion's fastest-ever launch by patient uptake and sales. As a consultant, Rich advises life sciences companies on product launch planning, commercial strategy, and licensing/business development, with depth in oncology, specialty and rare disease, neuroscience, and immunology. He holds a BS in Mechanical Engineering and an MBA from the University of Michigan.

William Rose

Senior Director of Program Management

William serves as Senior Director of Program Operations, bringing more than two decades of leadership in pharmaceutical and nuclear manufacturing to the role.

Most recently, William served as Director of Operations at Cardinal Health Nuclear Manufacturing Services, where he oversaw ten commercial cGMP manufacturing facilities spanning generic and CDMO operations. In that role, he was responsible for operations, Chemistry, Safety, Quality, Delivery, and employee experience across every site, while driving strategic initiatives that grew profitability, boosted operational efficiency, and expanded market share.

Before Cardinal Health, William served as Head of Viral Vector at Lonza Biologics, where he led the production of therapeutic proteins under cGMP conditions. His career also includes radiopharmaceutical facility design and build, equipment selection, coupled with validation and qualification under 21CFR part 11.

Chris Marcinek

Controller

Chris serves as the Company’s Controller and is a seasoned healthcare finance professional with more than 25 years of diversified accounting and finance experience across both pharmaceutical and non-pharmaceutical industries.

Most recently, Chris served as Director of Accounting at MTF Biologics, where he oversaw all accounting functions, including monthly financial closes and consolidated financial reporting processes within a multi-entity reporting environment. Prior to MTF Biologics, Chris served as Corporate Controller at Matinas BioPharma, Inc., a publicly traded biopharmaceutical company focused on an intracellular, oral drug-delivery platform. Before that, he was Assistant Controller at electroCore, Inc., a publicly traded medical device company whose principal product is an FDA-approved, proprietary vagus nerve stimulation device designed to relieve the symptoms associated with migraine and cluster headaches.

Earlier in his career, Chris held various accounting and finance positions in public accounting, including at PwC, as well as at other private and publicly traded companies.

Chris is a Certified Public Accountant (CPA) and Certified Internal Auditor (CIA). He holds a Bachelor of Arts degree and a Master of Applied Science degree from Brooklyn College in Brooklyn, New York.

Sathya Arunachalam

Associate Director of Analytical Development

Sathya has over 25 years of hands-on experience in Analytical Research and Development, with deep expertise across a wide range of dosage forms, including oral solids, liquids, semi-solids, injectables, nasal sprays, and medical devices. His experience spans Drug Substance, Drug Product, and Drug Discovery programs. Previously, he served as Associate Director at Hikma Pharmaceuticals and has held roles at Quagen Pharma, G&W Laboratories, Wockhardt, Teva Pharmaceuticals, Perrigo, Par Pharmaceutical, Syngene, Cipla, and Strides Arcolabs. He holds a Master of Pharmacy (M.Pharm) from Dr. M.G.R. Medical University, India.

Dr. Santosh Alluri

Senior Manager of Pharmaceutical Development

Santosh is a skilled radiochemist with experience in developing precursors, radiolabeling strategies and manufacturing radiotracers, and advancing multiple tracers from discovery through IND-enabling studies. He is skilled in manual & automated radiosynthesis, tracer in vivo validation, CMC process development, GMP manufacturing, QC method development, and radiometabolite studies. Dr. Alluri was most recently a radiochemist at the University of Chicago, and previously an Associate Research Scientist at Yale, and a post-doc fellow at the University of Missouri. He holds a PhD in Radio & Organic Chemistry from the University of Oslo, and a M.Sc in Structural Chemistry & Spectroscopy from the University of Leipzip in Germany. Dr. Alluri is also the co-author of 13 peer reviewed publications and one provisional patent.

Meysam Bahrami

Senior Manager of QC

Meysam has over 10 years of experience in radiopharmaceuticals spanning roles at Progenix, Lantheus, and Evergreen. His background is focused on analytical chemistry and GMP environments within radiopharmaceutical companies. At Evergreen, he served as lead QC manager for their Springfield site overseeing the QC lab team. He has experience in method development, validation, transfer, stability programs, and batch release testing, while driving effective investigations, CAPA, and audit readiness.

Rinku Soni

Associate Director of Program Management

Rinku Soni joined our team in January. She holds a Masters degree in Analytical Chemistry and has worked on a variety of solid oral dosage forms, liquid formulations, CDMO based sterile manufacturing and radiopharmaceuticals. She comes onboard with more than 20 years of experience in the pharmaceutical industry in a variety of roles ranging from Analytical Chemist, Quality Compliance, R&D formulations scientist, Technical Services Validation scientist, Cleaning Validation scientist, Equipment qualification scientist, and has experience in regulatory and project management.

Mike Manley

Associate Director of Program Management

Mike has global project management experience leading 40+ program teams for Endo, BMS and Sandoz. He has 25+ years of pharmaceutical/ medical device experience supporting drug development and CMC strategy for generic and brand initiatives. He has driven global cross-functional teams for biologics, sterile fill and combination product development efforts including milestone alignment for development initiatives including supply. Mike is experienced in quality management and has supported compliance initiatives through commercial readiness.

Javed Mahmood

Senior Director, Clinical Development

The Faces Behind Our Science

Alex Agnoletto

Dr. Indranil Nandi, PhD

Dr. Kyle Hoffmann, PharmD

Dr. Serge Lyashchenko, PharmD

Sharon Roded

Pietro Bubba Bello

Yehudah Livneh

Sean Campbell

Huw Jones

Richard Brodsky

William Rose

Chris Marcinek

Sathya Arunachalam

Dr. Santosh Alluri

Meysam Bahrami

Rinku Soni

Mike Manley

Javed Mahmood

Upsized and Oversubscribed Seed Round Completed at $40 Million